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MSCs are deﬁned as mesenchymal stem cells or mesenchymal stro-
mal cells, but represent commonly a large set of different types of cells.
Indeed, MSCs have been isolated from different types of tissues, includ-
ing in particular the bone marrow (BM-MSC), umbilical cord blood, ad-
ipose tissue (we will deﬁne them as adipose derived stromal cells), but
also peripheral blood, fetal liver, lung, amniotic ﬂuid, or placenta (for a
review, [1]). All these types of MSCs retain similar characteristics with
the ability to adhere strongly to plastic surfaces, are characterized by
surface markers (CD14− or CD11b−, CD19− or CD79α−, CD34−,
CD45−, HLA-DR−, CD73+, CD90+, CD105+) and with the potential
to be differentiated into chondrocytes, osteoblasts and adipocytes under
standard in vitro differentiating conditions [1]. Despite some common
features with regard to the immunophenotype and differentiation po-
tential of MSCs, these cells do vary in accordance with their direct inter-
action with other cells or via a paracrine fashion to the surrounding
microenvironment.
The ﬁeld of MSCs in tumor development has progressed tremen-
dously since the early 2000s (for a review, [1]). In the setting of cancer
therapy, the TREAT-ME1 is the ﬁrst clinical trial worldwide using genet-
ically altered MSCs for the treatment of advanced gastrointestinal tu-
mors [2]. In this study, MSCs have been engineered to express the
thymidine kinase of the herpes simplex virus (HSV-Tk) under the con-
trol of RANTES (CCL5) promoter, which is highly active in MSCs in the
tumor context [3]. The RANTES/CCL5 promoter should allow tumor
stroma-targeted expression of the thymidine kinase gene, which
when phosphorylated by the prodrug, ganciclovir, can be incorporated
into replicating DNA leading to cell death.
Although this trial has demonstrated the safety usage of modiﬁed
MSCs, it is nevertheless important to execute caution since the biologi-
cal properties of MSC in the tumor microenvironment have been com-
plicated by the limited lineage-speciﬁc markers and the inter- and
intra-clonal heterogeneity of MSCs. Thus, the main focus of this review
is to provide an updated review of the current understanding of MSCs
and its interaction with tumor cells. Apart from the unique feature of
MSCs migrating toward injured and pathological lesion tissues, we
will focus on the role of MSCs during the development of cancer,Fig. 1. Factors favoring MSc homing towards tumor cells. Cancer cells secrete a number of che
chemokine receptors at their surface. Chemokines can be directly released in the extracellu
PDGFF-BB, NT-3, MIF and factors such as LL-37, uPA and cyclophilin B released by tumor cells
secrete cytokines such as CXCL1, CXCL2, CXCL12 or IL-6 and metalloproteinases (MMPs), the lemphasizing on the six hallmarks of cancers, i.e. how MSCs aid in
(i) enabling replicative immortality to cancer cells (ii) sustaining prolif-
erative signal of cancer cells and cancer stem cells (iii) its action on
epithelial and mesenchymal transition and metabolism of cancer cells
(iv) how MSCs can evade growth suppressor (v) resist cell death and
(vi) induce angiogenesis.
2. Homing of MSCs to tumor sites
Chemokines or more generally cytokines are amongst the major
players responsible for MSC migration to tumors (Fig. 1), which is not
surprising since chemokines are abundantly produced in tumor sites
[4–6]. In addition, treatment of tumor could also promote themigration
of MSCs toward tumors. Irradiation of breast tumor cells has been
shown to enhance the release of TGFβ1, VEGF and platelet-derived
growth factor BB (PDGF-BB) by tumor cells, which enhance the migra-
tion of MSCs towards cancer cells [7]. Furthermore, the migratory
event was dependent on the upregulation of CCR2 on MSCs following
exposure to irradiated cancer cells.
Using ratMSCs,Menon et al. have shown that themigration of MSCs
towards cancer cells involved the up-regulation of CXCL12 in MSCs [8].
CXCL8 has been implicated for the migration of MSCs derived from
human umbilical cord blood and human bonemarrow [9] towards glio-
mas. Interestingly, even when MSCs are isolated from the same source,
i.e. BM-MSCs, different cytokines have been implicated to provide the
signaling cues to the migration of MSCs toward cancer cells. For exam-
ple, CCL2 and CCL25 are the major chemokine responsible for stimula-
tion human BM-MSC to migrate towards breast cancer [10] and
multiple myeloma (MM) [11] respectively. Migration of human BM-
MSCs towards hepatoma cells involves the release of CCL15 and CCL20
by cancer cells [12] and the chemokinemacrophage inhibitory factor se-
creted by various cancer types can attract human BM-MSCs in a CXCR4-
dependentmanner [13]. Thus, the type of cytokine released that are cru-
cial formediatingMSCmigration is, in part, dependent on the tumor cell
type and its niche as illustrated in Fig. 1.
Another wayMSC can mediate tumor tropism is via secretion of ex-
tracellular vesicles such as the exosomes. Exosomes are small mem-
brane vesicles secreted from cells that are important mediators ofmokines (CCL2, CCL15, CCL20, CCL25, CXCL1, CXCL8) which attract MSC through speciﬁc
lar medium or incorporated into vesicles. Other cytokines including VEGF, HGF, TGFβ,
will affect the tropism of MSCs. Moreover, upon interaction with cancer cells, MSCs will
atter with the ability to degrade extracellular matrix and favor migration.
292 L. Gwendal, L. Paula Y / Biochimica et Biophysica Acta 1866 (2016) 290–299intercellular communication and are implicated in the development of
pathological processes. Cholangiocarcinoma cells have been shown to
secrete these extracellular vesicles that promote the release of CXCL1,
CCL2 and IL-6 from MSCs which aids in the migration of MSCs toward
the tumor cells. In addition, conditioned media from MSCs exposed to
these tumor derived extracellular vesicles could promote tumor cell
proliferation through IL-6 signaling [14].
Besides cytokines, other factors are potentially involved in MSC tro-
pism. In vivo inhibition of the leucine-leucine 37 peptides (LL-37) sig-
niﬁcantly reduce engraftment of MSCs into ovarian tumors [15].
Among other factors potentially involved in MSC chemotaxis to cancer
cells, cyclophilin B and hepatocyte growth factor (HGF) have also been
suggested [16]. Transforming growth factor-ss1 (TGF-ss1) and
neurotrophin-3 (NT-3) contribute also to the glioma-directed tropism
of human MSCs [17]. A number of human solid tumor cell lines express
high levels of uPA (urokinase plasminogen activator) and soluble uPAR
(urokinase plasminogen activator receptor) in tumor cell-conditioned
media. uPA is one of the factors responsible for the migration of MSCs
towards neuronal stem cells [18]. This paracrine signaling loop between
the tumors and MSC resemble those in the injured tissues where MSCs
and other inﬂammatory cells are recruited to the injury sites by ﬁbrino-
lytic factors such as uPAR. These factors released fromMSC in turn set a
proteolytic environment and activate another set of proteases such as
metalloproteinases (MMPs) which enable the release of cytokines and
chemokines [19]. Several groups have also highlighted the crucial role
MMP-1 produced by MSCs that will favor tropism through a cross talk
with the CXCL12/CXCR-4 axis [12,20,21].
3. MSCs aid in replicative immortality to cancer cells
One of the hallmarks of cancer is the ability to undergo continuous
proliferation. This replicative immortality is triggered by telomere dys-
function, suppression of tumor suppressors such as p53 and p16/pRb
and oncogene activation. It has beendemonstrated that ratMSCs under-
go spontaneous transformation in vitro, possibly due to epigenetic si-
lencing of p16 [22]. A recent study investigated the characteristics of
rat MSCs before and after spontaneous transformation. In agreementFig. 2. Amultitude of factors favoring tumor growth by MSCs. Cancer cells can release IL-1β or
multiple cytokines including in particular CXCL1 CXCL8, CCL2, CCL5 and IL-6. CCL5 is involv
mechanism. Moreover, CCL5 production by MSCs can also be induced by other factors secrete
increase the secretion of IL-1β, IL-6, TNF-α, CXCL8, VEGF or MMP-2 by MSCs. MSCs release M
cancer cells, MSCs will acquire a CAF phenotype favoring tumorigenesis with the production owith the earlier study, p16 was markedly silenced. In addition, this re-
search group found that transformed MSCs contain high levels of a
p53 mutant that loses its ability to bind to surviving gene. As a conse-
quence, surviving expression wasmarkedly upregulated in these trans-
formed MSCs which exhibited characteristics of cancer stem-like
features such as loss of contact inhibition, multi-potency to mesenchy-
mal lineages and anchorage-independent growth [23].
4.MSCs can sustain proliferative andmetastatic signal of cancer cells
Multiple studies have shown pro-tumorigenic effects of MSCswhich
are summarized in Fig. 2. One of the ﬁrst studies that reported the in-
volvement of chemokines in the increased metastatic ability of cancer
cells in the presence of MSCs was published by Weinberg's group. The
authors showed that MSCs upon contact with cancer cells, MSCs re-
leased the chemokine CCL5, which was responsible for the increased
metastasis of breast cancer cells [3]. The potential of CCL5 secreted by
stromal on tumor invasion has also been observed with adipose-
derived stromal cells [24]. Luo et al. subsequently showed thatMSCs se-
crete CCL5 which suppresses AR signaling in prostate cancer cells (PCa)
by enhancing the expression of HIF2α in PCa and promotes metastasis
[25]. One explanation of the hypersecretion of CCL5 by MSCs could
arise from the release by tumor cells of IGF-1 (Insulin-like-Growth
Factor-1) [26] or the pro-inﬂammatory peptide Leucine-Leucine-37
(LL-37), which would induce not only the production of CCL5 but also
of IL-6, IL-10 and VEGF which would increase angiogenesis and the
growth of ovarian tumors [15]. IL-6 by itself has been shown to be pro-
duced at high levels by MSCs when they are conditioned by tumor cells
and to be involved as well as VEGF secretion in the more rapidly grow-
ing of ovarian cancer cells in coculture with MSCs [27]. This role of IL-6
has also been observed in the dialog between MSCs and breast cancer
cells [28].
Tumor-derived osteopontin (OPN) also induces MSC production of
CCL5, which binds to integrin cell surface receptors [29]. MSCs stimulate
cancer cell metastasis and upon contact with cancer cells acquire MSCs
retrieved from sites of metastases exhibit a CAF phenotype with alpha-
smooth muscle actin, tenascin-c, CXCL12, ﬁbroblast-speciﬁc protein-1miR-146a (through vesicles) which can enhance NF-κB activity in MSCs and the release of
ed in an increased metastasis of cancer cells, in some cases through HIF2α-dependent
d by cancer cells such as osteopontin (OPN), IGF-1 or LL-37. LL-37 has also the ability of
MP-2, MMP-9 and HGF, which will promote metastasis. Finally, upon interaction with
f FSP-1, FAP, α-SMA, CXCL12, BMP4 and IL-6.
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cer cells interactingwithMSCs appears as a crucial point in terms of the
ﬁnal effect ofMSCs. Indeed,we have demonstrated that the conditioned
mediumofmetastatic breast cancer cells was able to induce the produc-
tion of a number of chemokines (in particular CXCL1, CXCL2, CXCL3,
CXCL5, CXCL6, CXCL8, CCL2, CCL5, CCL8, CCL20) upon release of IL-1β
by cancer cells and subsequent activation of NF-κB pathway in MSCs.
Chemokines produced by MSCs are in turn able to increase the motility
of breast cancer cells creating a vicious circle [30]. Moreover, it should
be also noted that MSCs naturally produce high levels of chemokines
CXCL1 and CXCL5 which increase the migration of Polyoma Virus mid-
dle T antigen (Pymt) mouse breast cancer cells [31].
Similar chemokines have been shown to be important for the pro-
moting effects ofMSCs on a number of other types of cancers. Colorectal
cancer cells (CRC) induce the production of CXCL8 by MSCs, which in
turn increases endothelial cell proliferation, CRC proliferation, tumor
formation and angiogenesis in vivo [32]. MSCs isolated from gastric tu-
mors (GC-MSCs) have a higher ability than BM-MSCs to stimulate the
proliferation and growth of gastric cancer cells. GC-MSCs produce
higher levels of pro-angiogenic factors such as VEGF, CXCL8 and
CXCL2. Blocking of CXCL8 was sufﬁcient to reduce the growth promot-
ing effect of GC-MSCs conditioned medium [33].
Another type of action of MSCs, which sometimes also affects che-
mokine signaling, corresponds to the MSC-derived exosomes which
can modulate tumor growth and invasion. It has been shown that
exosomes derived from metastatic melanoma cells can educate bone
marrow derived cells toward a pro-metastatic phenotype throughmes-
enchymal epithelial transition (MET) and by increasing the leakiness of
blood vessels [34]. Exosomes from MSCs are also able to promote both
in vitro and in vivo tumor growth of nasopharyngeal carcinoma through
in particular the production of FGF19 in the exosomes [35]. Exosomes
produced byMSCs confer the resistance to 5-ﬂuorouracil treated gastric
cancer cells. These exosomes from MSCs enhance the calmodulin-
dependent protein kinase (CaM-Ks) and RAF/MEK/ERK signaling in gas-
tric cancer cells [36].
Growth factors are also playing a role in the control of tumor
development by MSCs. TGFβ1 secretion by prostate cancer cells isFig. 3. Mechanisms underlying the anti-tumor effect of MSCs. MSCs release high levels of in
stimulatory effect on cancer cells. Another way for MSCs to repress tumor growth is the sec
catenin signaling. Through the release of miR-16 in exosomes, MSCs will reduce the producti
inhibitory effect on translation initiation factors such as eIF4E, eIF4GI as well as on Akt an
production of PDGF-BB and IL-1β by MSCs, which in turn reduces angiogenesis and tumor groable to enhance the migration of MSCs towards cancer cells in vitro
[37]. TGFβ1 secretion by prostate cancer cells induces MSC
transdifferentiation into CAFs. In turn, such CAFs will enhance the inva-
siveness of prostate cancer cells [37]. MSCs induce the migration of
breast cancer cells also through the release of TGF-β and the activation
of rho-associated kinase, focal adhesion kinase and matrix metallopro-
teinases [38]. Carnet et al. have shown that BM-MSCs enhance lung car-
cinoma tumor growth through trans-shedding of amphiregulin (AREG)
from the tumor cell membrane by TNFα converting enzyme carried by
the BM-MSC plasma membrane. The released soluble AREG activates
cancer cell growth and invasion [39]. The isolation of MSCs from gastric
carcinoma has shown that these educated MSCs could enhance tumor
growth through the release of HGF [40]. Umbilical cord derived mesen-
chymal stem cells can increase tumor growth and metastasis of cholan-
giocarcinoma cells, through an induction of Wnt/β-catenin signaling in
cancer cells [41]. BM-MSCs and acute myeloid leukemia cells interact
through a mutual induction of Notch signaling in both cells which sup-
ports AML growth [42].
On the other hand MSCs could exhibit tumor suppressive effect
(Fig, 3). It was shown that conditioned media derived from human
fetal MSCs express high levels of the insulin growth factor binding pro-
teins IGFBPs and can sequester free insulin-like growth factors (IGFs) to
inhibit hepatocellular carcinoma cell proliferation via cell cycle arrest
[43]. Dickkopf-related protein 1 (Dkk-1) secreted by the MSCs inhibits
growth of breast cancer cells via depression ofWnt signaling and in par-
ticular by reducingβ-catenin levels in breast cancer cells [44]. Other sig-
naling pathways including the MAPK and Akt are also affected. Indeed,
BM-MSCs can reduce the proliferation, viability and migration of
NSCLC through the down-regulation of translation initiation factors
(eIF4E and eIF4GI) and MAPK signaling [45]. Moreover, Khakoo et al.
have shown that MSCs have anti-tumorigenic and pro-apoptotic effects
on Kaposi sarcoma cells by suppressing Akt activity in cancer cells [46].
MSCs produce exosomes containing mir-16 which is able to down-
regulate VEGF and VEGFR production by breast cancer cells and in
turn reduce tumor growth in vivo, with a decrease of vascularization,
even if it should be mentioned that most studies have shown a pro-
tumorigenic effect of MSCs on breast cancer [47]. In addition, onesulin growth factor proteins (IGFBP) which can sequester IGF-1 and prevent its growth
retion of Dickkopf-related protein 1 (Dkk-1) which has negative effects on Wnt and β-
on of cancer cells. Moreover, even if the factors involved are not known, MSCs can have
d MAPK pathways. On the other hand, in some instances, tumor cells can inhibit the
wth.
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exosomeswhich render hepatocellular carcinoma cells sensitive to che-
motherapy [48]. It remained unclear why majority of the studies are in
favor of positive effects, which could explainwhy themechanisms of in-
hibition of growth or metastasis have been less investigated.
5. MSCs can sustain proliferative signal in cancer stem cells
Cancer stem cells show unique properties in terms of cancer initia-
tion, enhanced metastasis and drug resistance. Interestingly, several
studies have shown that MSCs could enhance cancer cell stemness (as
illustrated in Fig. 4). This can occur through a direct action on classical
genes involved in stemness. MSCs isolated from ovarian tumors in-
crease the number of cancer stem cells (CSCs) through the bone mor-
phogenetic protein BMP2 and BMP4 production [49]. Moreover, the
same group has shown that ovarian tumor cells could secrete Hedgehog
(HH), which in turn stimulate the production of BMP4 [50]. BMP4 is re-
sponsible for the enrichment of cancer stem cells and chemotherapy re-
sistance [50]. FoxP2 seems also involved as coculture of MSCs with
breast cancer cells triggers an increase of mir-199 and mir-214 expres-
sion in breast cancer cells, leading to an enhancedmetastasis and cancer
stem cell phenotype of breast cancer cells [51]. These 2 miRs repress
Forkhead-Box P2 (FoxP2) expression and is responsible for increasing
the number of cancer stem cells, favoring tumor initiation andmetasta-
sis [51]. Chemokines and some cytokines are known to play critical role
in modulating cancer stem cells. Colon cancer cells produce IL-1α and
IL-1β which induce the secretion of PGE2 by MSCs. PGE2 is then able
to cooperate with IL-1 to increase the production of cytokines such as
IL-6, CXCL1 and CXCL8 by MSCs, leading to activation of beta-catenin
pathway and an increase of stem cell properties of cancer cells [52].
A number of other studies have highlighted this role of CXCR2 li-
gands. MSCs are able to increase the number of breast CSCs and in par-
ticular the percentage of aldehyde dehydrogenase (ALDH)-positive cells
[53]. Coculture of MSCs with breast cancer cells increases the produc-
tion of CXCR2 ligands (CXCL1, 5, 6, 7, 8) which are able to increase the
percentage of CSCs [53]. Moreover, CXCL7 produced by MSCs can up-
regulate the levels of CXCR2 ligands. The same study has shown that
breast cancer cells produce IL-6with the ability to induce the expressionFig. 4.MSCs promote the stemness of cancer cells. Upon release of Hedgehog (HH) by tumor cel
released by cancer cells induces the production of PGE2 byMSCs, leading to the higher release o
and the markers of stemness including Aldehyde dehydrogenase (ALDH), CD-133, ZEB-1, c-my
199 and miR-214 targeting FoxP2 expression to increase stemness.of CXCL7 in MSCs [53]. Conditioned media from MSCs contains cyto-
kines (IL-6, CXCL8) and induces expression of pluripotency factors (c-
myc, Oct-4, Sox2) as well as the AMPK/mTOR and NF-κB pathways in
colorectal cancer cell lines [54]. A similar study has shown that IL-6 pro-
duced by MSCs is responsible for the increase in the proportion of CSCs
(CD133-/CD166-/EpCAM-) in the population of colorectal cancer cells,
through an activation of the JAK2-STAT3 pathway in cancer cells [55].
Luo et al has shown that upregulation of CCL5 expression in BM-MSCs
and PCa cells, afterMSCs inﬁltrated into the tumor, subsequently down-
regulated androgen receptor (AR) signaling and increases the percent-
age of cancer stem cells [56]. This increase in the number of PCa stem
cell then leads to the upregulation of matrix metalloproteinase 9, ZEB-
1, CD133 and CXCR4 molecules, and enhanced the metastatic ability of
PCa cells [56].
6. MSC's action on epithelial and mesenchymal transition and
metabolism of cancer cells
Epithelial-mesenchymal transition (EMT) is a key event in tumor in-
vasionwhere the epithelial cell layers lose their apico-basal polarity, un-
dergo matrix remodeling resulting in the spread and invasiveness of
cancer cells. MSCs have been reported to stimulate EMT and induce
stem-like properties that allow the cancer cells to acquire enhancedmo-
tility and survival through the circulation. MSCs and cancer cells ex-
change multiple types of materials including exosomes, mitochondria
and also cell membrane components in a bidirectional way [57]. BM-
MSCs are able to transfer mitochondria to breast cancer cells, resulting
in an enhanced oxidative phosphorylation, cancer cell growth and inva-
sion [58]. Co-culture of breast cancer cells with MSCs led to an EMT-
phenotype as characterized by downregulation of epithelial markers
such as E-Cadherin with a corresponding upregulation of mesenchymal
markers, vimentin, N-cadherin and snail [59]. Similarly, conditioned
media derived from MSCs have been shown to trigger EMT in cancer
cells, thereby promoting the metastatic potential of these cells [60].
A number of reports have shown that the interaction of MSCs with
cancer cells leads them to acquire a cancer associated ﬁbroblasts
(CAFs) phenotype [1]. CAFs are generally characterized by a high ex-
pression of CXCL12, alpha smooth actin (α-SMA) and ﬁbroblast surfacels, MSC release BMP4, whichwill increase the number of cancer stem cells. IL-1α and IL-1β
f IL-6, CXCL1, CXCL5, CXCL7 and CXCL8 leading to an increase of cancer stem cell properties
c, Oct-4, Sox-2, NF-kB, JAK2/STAT3 and CXCR4. MSCs also release vesicles containing miR-
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growth by recycling products of the anaerobic metabolism of cancer
cells. MSCs could also enhance cell survival through upregulation and
secretion of anti-oxidant, stanniocalcin-1 (STC1).MSC-derived STC1de-
creases levels of reactive oxygen species (ROS), mitochondrial mem-
brane potential (MMP), and increases lactate production, leading to a
decreased ROS-induced apoptosis andenhanced the energymetabolism
of cancer cells i.e. the Warburg Effect [62].
Further, MSCs could modulate the metabolism of cancer cells and
proliferation through secretion of exosomes, the reverse is also true. In
a recent study, exosomes produced from the prostate cancers could
impair the adipogenic differentiation of MSCs, but favoring the differen-
tiation of MSCs into myoﬁbroblasts [63]. In turn, the exosome differen-
tiated MSCs are to promote vascularization and tumor growth [63].
Coculture of MSCs with cancer cells can result in a morphological
change of MSCs dependent on the expression of E-cadherin and IL-1β
by cancer cells. Pharmacological inhibition of FAK,MAPKK, and actin po-
lymerization completely abrogated MSC morphological changes [64].
Apart from cancer cells, macrophages have also been shown to interact
with MSCs and increase the production by MSCs of a number of
cytokines including IL-6, CCL2, 5, 7, 20 and CXCL1, 3, 6, and 8 [65]. Alter-
natively,MSCs have also been reported to acquire epithelial characteris-
tics through fusion with gastrointestinal epithelial cells [66], which has
been also observed between MSCs and breast cancer cells [67]. At least
20% of CAFs isolated from gastric cancer were derived fromMSCs origi-
nated from the bone marrows. These CAFs, like MSCs, expressed high
levels of trophic factors including IL-6, Wnt5α and BMP-4 and are re-
cruited to tumor sites in TGF-β and CXCL12 dependent way [68].
The process of acquiring CAF phenotype or possible fusion with the
surrounding epithelial cells is not well elucidated. Some reports deﬁne
two classes of polarized MSCs. Toll like receptor (TLR)1–6 have been
identiﬁed on primary human MSCs and have been reported that TLR
stimulation enhanced the migratory function of MSCs [69]. TLR4-
primed MSCs are polarized into pro-inﬂammatory MSC1 phenotype;
whereas TLR3-primed MSCs are polarized into the classical immuno-
suppressive MSC2 phenotype [70]. The classiﬁcation into the two phe-
notypes is mainly based on a distinct cytokine proﬁle which includes
an overexpression of TGF-β and its downstream effectors SMAD3 and
SMAD4. MSC1 are capable of inhibiting tumor growth and metastasis,
whereas MSC2 do the reverse [71].Fig. 5.A central role of PGE2 and IDO in the immunosuppressive effect ofMSCs. MSCs produce P
dendritic cells, increase the production of IL-4 by Th2 cells and reduce the release of IFNγ b
Indoleamine 2,3-dioxygenase (IDO) which is able reduce tryptophan levels and thus inhibit th7. HowMSC can evade growth suppressor
One of the major features of MSCs is their immunosuppressive po-
tential, which has been extensively studied and represents an attractive
point for therapeutic purposes for immunological diseases [72] (Fig. 5).
MSCs could regulate the proliferation, activation and effector function of
T lymphocytes, antigen presenting cells and NK cells via direct cell-to-
cell contact or production of soluble factors including prostaglandin
E2, indoleamine 2,3-dioxygenase, tumor necrosis factor-α stimulated
gene/protein 6, nitric oxide, and transforming growth factor (TGF-β)-1
[72].
MSCs are able to inhibit the proliferation of T cells, but also B cells
and NK cells both in vitro and in vivo. This can favor tumor growth in al-
logeneic animals [73]. The pro-tumorigenic action of MSCs on tumor
growth and metastasis of breast cancer cells, involves a lower cytotoxic
activity of splenocytes, NK cells and CD81 T cells in vitro [74]. Moreover,
tumors treated MSCs have signiﬁcantly lower percentages of
CD31NKp461 NKT-like, higher percentages of CD41Foxp31 T cells, in-
creased serum levels of Th2 and decreased serum levels of Th1 cyto-
kines, and signiﬁcantly higher number of CD41 cells expressing IL-10
[74]. Immunosuppressionmediated byMSC can occur via paracrine sol-
uble factors. For example, the prostaglandin E2 (PGE2) released from
MSCs can trigger the production of IL-10 by macrophages [75] and pre-
vent thematuration ofmonocytes into dendritic cells [76]. Furthermore,
MSCs could also push Th1 cells to secrete less IFN-ɣ and caused the Th2
cells to increase their secretion of the immunosuppressive IL-4 [77].
MSCs derived from cervical tumors have been shown to downregulate
the surface HLA class I molecules (HLA-A*0201) [78]. As a consequence,
production of IL-10 is enhanced which aid in the establishment of an
immune-silenced and quiescent niche. Likewise, MSCs derived from
breast cancer tumors also exhibited high levels of immunosuppressive
factors including IL-10, IL-4 and TGF-β1 [79].
Indoleamine 2,3-dioxygenase (IDO) is a rate-limiting enzyme in the
degradation of tryptophan (Mellor AL andMunn DH, 1999). Growth ar-
rest in T lymphocytes was observed when the cells were exposed to
tryptophan shortage provoked by IDO [80]. This resulted in the ability
of the tumor cells to escape from immune surveillance. Human MSCs
express IDO protein and exhibit functional IDO activity upon stimula-
tion with IFNγ and inhibit allogeneic T-cell responses [81]. IFNγ-pre-
conditioned MSCs not only repress T cell proliferation but could alsorostaglandin E2 (PGE2)whichwill enhance the production of IL-10 frommacrophages and
y Th1 cells and NK cells. Upon stimulation with IFNγ, MSCs produce also high levels of
e growth of numerous cells including B cells, T cells and NK cells.
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[82]. Inducible nitric oxide synthase (iNOS) produced by the murine
MSCs also exhibit similar T cell suppression effect which led to enhance
melanoma cell tumor growth [83].
Another mechanism of MSC immunosuppression is mediated
through high expression of CCR2 ligands which could recruit immuno-
suppressive cells such as CD11b+Ly6C+ monocytes, F4/80+, macro-
phages, and CD11b+Ly6G+ neutrophils to the tumor [84]. In the
same line, MSCs from follicular lymphoma patients promote monocyte
differentiation toward a proangiogenic and lipopolysaccharide-
unresponsive phenotype close to that of (TAM) tumor-associated mac-
rophages and produce higher levels of CCL2 upon coculture withmalig-
nant B cells [85]. Moreover, the nature of cancer cells is also important.
Indeed, it was shown recently that upon interaction with breast cancer
stem cells (CSCs), MSCs can promote the polarization of PBMC in Tregs
and Th17. This effect is dependent on the high interaction of CSCs with
MSCs through CXCR4 and connexin 43-dependent gap junction inter-
cellular communication [86].
8. Resist cell death
It is interesting to point out that MSCs are also able to confer a resis-
tance to cancer drugs (Fig. 6), aswell as other DNAdamaging agent such
as irradiation. Co-culture of MSCs and breast cancer cells confer resis-
tance against trastuzumab via activation of the nonreceptor tyrosine ki-
nase c-Src and downregulation of the phosphatase and tensin homolog
(PTEN) [87]. MSCs have also been shown to confer cisplatin and
bortezomin resistance in cancer cells by the local release of soluble fac-
tors such as IL-6 and CXCL8 [88] and IL-6, IL-10, IGF-1, VEGF and Dkk-1
[11]. Someof these cytokines have been implicated in their ability to en-
hance stemness of cancer cells; hence, it is not surprising that another
mechanism by which MSCs confer resistance to chemotherapy is via
their ability to harness properties similar to those of cancer stem cells.
In a study, targeted methylation of the promoters of tumor suppressor
genes in MSCs have caused the cells to transform towards tumor-
initiating cells, and these cells exhibited increased resistance to cisplatin
treatment [89]. MSC could also promote dormancy of breast cancer cellsFig. 6.MSCs favor the resistance to treatments. MSCs havemultiple effects on cancer cell resista
miR-23b in exosomes, which will in particular target Myristoylated Alanine Rich Protein Kinase
miR-222/223, which could potentially target cyclins. Moreover, MSCs can activate pathways su
increase the resistance of tumor cells to treatments. Upon chemotherapy, MSCs acquire the abil
5,8,10-heptadecatrienoic acid (KHT) and hexadeca-4,7,10,13-tetraenoic acid (16:4(n-3)). Final
which decreases the levels of ROS and increases lactate production, leading to an enhanced Wvia the exosome release of miR-23b which targets Myristoylated
Alanine Rich Protein Kinase C Substrate (MARCKS, a promoter of cell
motility and cycling, implicated in the pathogenesis of metastatic can-
cers) [90]. In the same line, breast cancer cells can stimulate the produc-
tion of miR-222/223 by MSCs which also induces the dormancy of
cancer cells aswell as the resistance to carboplatin treatments [91]. It re-
mains unclear whether miR-222/223 could target cyclins. Apart from
soluble cytokines, MSC could also release polyunsaturated fatty acids,
in particular, polyunsaturated fatty 12-oxo-5,8,10-heptadecatrienoic
acid (KHT) and hexadeca-4,7,10,13-tetraenoic acid (16:4(n-3)) [92].
Blocking the central enzymes involved in the production of these fatty
acids could effectively sensitize the cancer cells against chemotherapeu-
tic drugs.
MSCs have also been demonstrated to confer radioresistance. This is
due to the facts that MSCs express high levels of key DNA Damage Re-
sponse proteins including ATM, Chk2 and DNA Ligase IV; high levels
of the anti-apoptotic proteins, Bcl-2 and Bcl-XL, and low levels of the
pro-apoptotic proteins, Bim and Puma [93].
9. Modulation of angiogenesis by MSCs
One of the tumor-promoting effects of MSCs is derived from their
ability to promote angiogenesis, which is one of the major hallmarks
of cancer. Co-culture of MSCs with tumor cells led to elevated produc-
tion of angiogenic factors such as VEGF and IL-6 [27]. VEGF secreted
from MSCs has been shown to promote angiogenic sprouting in vitro
while MSCs were not observed to differentiate into endothelial cells
in vitro and in vivo [94]. Radiation therapy has been shown to increase
the release of CXCL12, PDGF-B by tumor cells, which not only attract
MSCs to the tumor site but also induces the newly recruited MSC to dif-
ferentiate into pericytes, and promote vasculogenesis and tumor
growth [95].
Studies have demonstrated that MSCs, as well as exosomes from
MSCs, could stimulate the cancer cells to secrete VEGF which in turn
promote tumor growth by activating extracellular signal-regulated ki-
nase1/2 (ERK1/2) pathway [96] respectively. Likewise, IL-6 secreted
by MSCs could also modulate angiogenesis and tumor cell proliferationnce to treatments. First, they can favor the dormancy of cancer cells through the release of
C Substrate (MARCKS) in cancer cells. Similar induction of dormancy is also promoted by
ch as PI3K/Akt, ERK and the expression of HER-2 and repress PTEN signaling, which all will
ity to produce higher levels for IL-6, CXCL8 and polyunsaturated fatty acids such as 12-oxo-
ly, MSCs increase the survival of cancer cells through the release of stanniocalcin-1 (STC1)
arburg effect.
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secretion of endothelial cell-derived endothelin-1 (ET-1) in cancer
cells [97]. ET-1 is a potentmitogen for endothelial cells, vascular smooth
muscle cells and tumor cells. Interestingly, Huang and colleagues not
only demonstrate that tumor growth can be efﬁciently inhibited by
targeting the IL-6/ET-1/Akt or ERK pathway of tumor-stroma interac-
tion [97] but that IL-6 secreted from MSC could induce non-cancer
stem cells to express markers of cancer stem cells, thus increasing the
ability to form tumor in vivo [55]. In breast cancer, elevated levels of
IL-6 have been correlated to increased metastatic spread [98] and poor
patient survival [4].
Under certain circumstances, MSCs could elicit an anti-angiogenic
response via a paracrine pathway that impairs the extent of endothelial
progenitor cell recruitment and capacity to form endothelial tubes [99].
Further, pro-angiogenic factorswere inhibitedwhich resulted in the ab-
rogation of tumor growth. Interestingly, MSC exosomes-derived from
bone marrow of mice harboring multiple myeloma had higher levels
of IL-6 and these MSCs were shown to promote tumor growth. In con-
trast, MSC exosomes-derived from normal bone marrow inhibited the
growth of the tumor cells [100].10. Remarks and perspectives
There is no doubt thatMSC can have profound effects the outcomeof
tumor development. The reason why this action is positive or negative
remains to establish some studies, including ours, begin to give some
tracks including the origin of MSCs or the nature of tumor cells used
in the experimental settings. Understanding how MSCs function is es-
sential to control or target MSCs in therapeutic strategies. It is striking
to observe that MSCs have the ability to act on all steps of carcinogene-
sis, including cancer stem cell arising, tumor growth, EMT, cancer me-
tastasis, angiogenesis as well as the resistance to different types of
disease treatments. Moreover, MSCs have a tropism for tumor sites
and are therefore particularly attractive to be considered as drug car-
riers. However, it is at present unclear if one should consider using
naïve MSC cells or MSC modiﬁed with appropriate therapeutic genes.
If so, the recommended dosage/site of isolation, donor variability, possi-
ble transformations of MSCs due to long term in vitro culture passages
and choice of viral vector used to introduce the therapeutic genes into
MSC should be carefully considered. Alternatively, one could consider
exploiting the therapeutic factors secreted fromMSCs that had prior ex-
posure to drugs. However, themechanisms involved are complicated by
the nature of material exchanges between MSCs and cancer cells, like
membrane fusion or mitochondria exchange and a variety of growth
factors, metabolites or fatty acids. These are often hard to qualify and/
quantify, making the relationship of MSCs and tumor cells moremyste-
rious and clinical applications for possible cancer treatment more
difﬁcult. The future challenges of the ﬁeld will certainly be the under-
standing of the key features of cells surrounding MSCs, which will dic-
tate the pro- or anti-cancer properties of MSCs. Moreover, to achieve a
better treatment of patients, future clinical approaches will need to
use strategies to inhibit the dialog between MSCs and cancer cells in
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